Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊苷或者烷化剂的治疗应该每年接受全血细胞计数,
监测
髓发
或继发性白血病的发生迹象。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊苷或者烷化剂的治疗应该每年接受全血细胞计数,
监测
髓发
或继发性白血病的发生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标本采集和运输当造成的标本质量问题占72。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦
代表本软件的观点;若发现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊苷或者烷化剂的治疗应该每年接受全血细胞计数检查,不良或继
性白血病的
生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标本采集和运输不当造成的标本质量问题占72。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若
现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托者烷化剂的治疗应该每年接受全血细胞计数检查,以监测
髓发育不良
继发性白血病的发生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标本运输不当造成的标本质量问题占72。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊苷或者烷化剂的治疗应该每年接受全血细胞计数检查,以监测髓发育不良或继发性白血病的发生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标本采集和运输不的标本质量问题占72。
声明:以上、词性分类均由互联网资源自动生
,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊苷或者烷化剂治疗应该每年接受全血细胞计数检查,以监测
髓发育不良或继发性白血病
发生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床本采集和运输不当造
本质量问题占72。
声明:以上例句、词性分类均由互联网资源自动生,部分未经过人工审核,其表达内容亦不代表本软件
观点;若发现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
泊苷或者烷化剂的治疗应该每年接受全血细胞计数检查,以监测
髓发育
良或继发性白血病的发生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标本采集和当造成的标本质量问题占72。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦代表本软件的观点;若发现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊苷或者烷化剂的治疗应该每年接受全血细胞检查,以监测
髓发育不良或继发
白血病的发生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标本采集和运输不当造成的标本质量问题占72。
声明:以上例句、词均由互联网资源自动生成,部
未经过人工审核,其表达内容亦不代表本软件的观点;若发现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊烷化剂的治疗应该每年接受全血细胞计数检查,以监测
髓发育不良
继发性白血病的发生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标和运输不当造成的标
质量问题占72。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表软件的观点;若发现问题,欢迎向我们指正。
Etoposide or alkylating agents should get complete blood counts (CBCs) yearly for evidence of myelodysplasia or a secondary leukemia.
依托泊苷或者烷化剂治疗应该每
全血细胞计数检查,以监测
髓
育不良或继
性白血
生迹象。
We find that unqualified specimen because of poor quality control of preanalysis account for 9 40%.of total complete blood count specimen.
40%,其中因临床标本采集和运输不当造成标本质量问题占72。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件观点;若
现问题,欢迎向我们指正。